Tests a new tuberculosis vaccine in newborns in sub-Saharan Africa
Tests the MTBVAC tuberculosis vaccine against BCG in healthy newborns.
Key facts
- Who runs it
- Biofabri, S.L
- Where
- Worcester, South AfricaSee the site
- Trial code
- Registry title
- Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 7,120 people, planned
- Started
- 17 Oct 2022
- Expected to end
- Feb 2029
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- MTBVAC
- BCG
- Record updated
- 10 February 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for healthy newborns within 7 days of birth, whose mothers are either HIV-negative or HIV-positive on treatment. It tests the MTBVAC tuberculosis vaccine against BCG.
- Age
- From 5 minutes to 7 days old (newborns within seven days of birth).
- Sex
- Boys and girls can both join.
- Earlier treatment
- Newborns who already had the BCG vaccine before joining cannot join.
- Biomarker or test result
- The mother needs a documented HIV test result taken within 30 days of delivery or within seven days after birth. If she is HIV-positive, she must be on antiretroviral therapy with a viral load under 50 copies/mL. HIV-exposed newborns need a negative HIV PCR result.
Main reasons for not taking part
- BCG vaccine before joining
- HIV-exposed newborn with a positive or missing HIV PCR result
- Mother had TB during pregnancy
- Close or household contact with a TB patient who has not finished treatment
- Suspected newborn sepsis or any severe birth defect
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- Male or female newborns within seven days of birth
- Written informed maternal consent, including permission to access maternal antenatal, postnatal, and infant medical records
- Infant participants and their caregivers available for trial follow-up and display the willingness and capacity to comply with trial procedures
- Newborns must be in good general health during pregnancy and delivery, as assessed by medical history and targeted physical examination
- Birth weight ≥ 2450 grams
- Apgar score at 5 minutes ≥ 7
- A maternal HIV test result (rapid test, enzyme-linked immunosorbent assay (ELISA), or Polymerase chain reaction (PCR)) taken within 30 days of delivery, or within seven days post-partum must be available and documented if HIV uninfected. If the mother is HIV infected, then she must be on antiretroviral (ARV) therapy as per in-country guidelines with a viral load of <50 copies/mL (within six months of labour)
- Estimated gestational age ≥ 37 weeks
- Mother has not participated in a clinical trial within three months prior to the infant's birth
- Mother has never participated in a TB vaccine trial before
- Infant may not participate in any other clinical trials
Who cannot take part
- Receipt of BCG vaccination prior to enrolment
- Skin condition, bruising or birth mark at the intended injection site
- Maternal HIV test (rapid test, ELISA, or PCR) result not available
- HIV exposed Newborn's HIV PCR result positive or not available
- Maternal history of TB during pregnancy
- History of close/household contact with a TB patient, antenatal or postnatal, whether maternal, other family member or another household member who has not yet completed TB treatment
- History or evidence of any systemic disease on examination, or any illness that in the opinion of the Investigator may interfere with the evaluation of the safety and immunogenicity of the vaccine. Neonatal jaundice not considered clinically significant is not an exclusion
- Significant antenatal, intrapartum, or postpartum complications that may affect the health of the newborn
- Clinically suspected neonatal sepsis
- Any severe congenital malformation
This trial is currently available in South Africa.
- South African Tuberculosis Initiative, Brewelskloof HospitalWorcester, South AfricaContact: Michele Tameris, MDTaking people
About the trial
What the trial wants to find out
The objective of this project is to demonstrate safety, immunogenicity and improved efficacy of the new live attenuated M. tuberculosis vaccine called MTBVAC in a Phase 3 efficacy trial in HIV-uninfected infants born to HIV-infected and HIV-uninfected mothers as compared to standard of care BCG vaccination. The proposal builds upon a group of TB vaccine development partners in Europe and sub-Saharan Africa established in a previous EDCTP-supported project. It creates an expanded consortium of clinical trial partners for the optimal implementation of a large infant efficacy trial of MTBVAC in high TB incidence settings. New capacity for efficacy trials in infants will be a valuable resource for the TB vaccine development community. The proposal will create a network of institutions in three TB endemic African countries with enhanced laboratory capacity to conduct TB vaccine immunology studies and to bio-bank samples to discover immune correlates of vaccine-mediated protection.
The 2 groups in the trial
- MTBVACTreatment being tested
Both MTBVAC and BCG vaccines are administered by intradermal route in the left deltoid region. One 0.05 mL reconstituted dose of MTBVAC will be defined based on the phase IIa results. MTBVAC is manufactured by Biofabri. MTBVAC is formulated (1.5 - 8.5 x104 CFU/dose, 1.5 - 8.5 x105 CFU/dose or 1.5 - 8.5 x106 CFU/dose (to be selected) and presented as a lyophilised pellet in 20 dose vials (0.05 mL/dose, after reconstitution with sterile water for injection). MTBVAC vaccine will be released and distributed by BIOFABRI, and imported to the sites following approval by the local regulatory authority. MTBVAC vaccine must be stored at +2°C to +8°C. Reconstituted MTBVAC vaccine must be stored at +2ºC to +8ºC and administered as soon as possible, within 4 hours of reconstitution. A single vaccine vial will be used for each participant.
- BCGExisting treatment, for comparison
BCG is a live attenuated M. bovis strain developed 100 years ago and is used as a preventive vaccine against tuberculosis. It is administered at birth. One 0.05 mL reconstituted dose of BCG contains 2.5 x 105 CFU. The control vaccine will be the BCG vaccine available and recommended in South Africa at time of the trial. BCG vaccine produced by AJ Biologics (formerly Staten Serum Institute) is the only BCG vaccine (Danish strain) currently licensed for routine use in South Africa. The recommended BCG injection volume for newborn infants (0.05 mL, after reconstitution with BCG diluent) contains approximately 2.5 x 105 CFU (range 1-4 x 105 CFU). BCG vaccine vials should be stored in the site pharmacy at 2-8ºC.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Randomised, Double-Blind, Controlled Phase 3 Trial to Evaluate the Efficacy, Safety and Immunogenicity of MTBVAC in Healthy HIV Unexposed (HU) and HIV Exposed Uninfected (HEU) Newborns in Tuberculosis-Endemic Regions of Sub-Saharan Africa
- Plain-language title
- Tests a new tuberculosis vaccine in newborns in sub-Saharan AfricaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Publications
- Record updated
- 10 February 2025